Aptorum Group Limited (Nasdaq: APM) subsidiary Smart
Pharmaceutical is excited to announce that the Smart Pharma Token
(“SMPT token”), is to be available for trading on IDAX
(https://www.idax.pro/) and LATOKEN (https://latoken.com/). IDAX
and LAtoken are two leading global cryptocurrency exchange
platforms. SMPT Token will commence trading on IDAX on or around
July 10, 2019, and shortly thereafter on LAToken.
The SMPT token is an ERC-1404 security compliant token with
ERC-20 and ERC233 compliance on the Ethereum blockchain. SMPT
tokenizes rights to a portion of the royalty income derived from
the eventual commercialization of intellectual property rights of
drug candidates to be discovered under our Smart-ACTTM
platform.
The Smart-ACTTM platform is a repurposed and new drug discovery
platform launched by the Smart Pharma Group which intends to
revolutionize drug discovery, repurposing and repositioning. In the
forthcoming developments, Smart Pharma Group would include the
incorporation of blockchain technology into the drug development
and discovery processes, initially through the adoption of the SMPT
token as the first step. We believe that blockchain technology will
significantly increase data transparency and bring distributed
power from participants worldwide to co-develop and evolve our next
Smart-ACTTM platform technology.
Smart Pharma Group recognizes that blockchain-based technology
will continue to play an important role in pharmaceutical
development and also has the capability to foster community-based
ecosystems of passionate and like-minded people in revolutionizing
the drug discovery industry who would like to be an integral part
of the process around projects.
Smart Pharma Community is jointly managed in collaboration with
Aenco Solutions Limited. For further information, please join the
discussions on our social media platforms which can be accessed as
follows.
Website: https://www.smtph.com
Telegram: https://t.me/Aenco
LinkedIn: https://www.linkedin.com/company/Aenco
Medium: https://medium.com/@Aencoin
Twitter: https://twitter.com/Aencoin
Facebook: www.facebook.com/Aencoin
Discord: https://discord.gg/NXpFcKQ
YouTube: YouTube.Aencoin.com
About Aptorum Group
Limited
Aptorum Group Limited (Nasdaq: APM) (“Aptorun”) is a
pharmaceutical company dedicated to developing and commercializing
a broad range of therapeutic and diagnostic technologies to tackle
unmet medical needs. Aptorum Group is pursuing therapeutic and
diagnostic projects in neurology, infectious diseases,
gastroenterology, oncology and other disease areas as well as
non-therapeutic areas such as surgical robotics and the operations
of its medical clinic in Hong Kong, Talem Medical, with the initial
focus on treatment of chronic diseases resulting from modern
sedentary lifestyles and aging population.
For more information about Aptorum Group, please visit
www.aptorumgroup.com.
About Smart Pharma Group
Smart Pharma Group includes Smart Pharmaceutical Limited
Partnership, a limited partnership registered in Seychelles, and
its general partner, SMTPH Limited, an international business
company incorporated under the laws of Seychelles. SMTPH Limited
and its subsidiaries are indirectly wholly owned by Aptorum Group
Limited.
Disclaimer and Forward-Looking
Statements
The SMPT tokens are currently not offered for sale to citizens,
nationals, residents (tax or otherwise), green card holders and/or
companies domiciled in the following: (a) the United States of
America; (b) Singapore; (c) Hong Kong (except for Professional
Investors); (d) the People’s Republic of China; (e) Samoa, (f)
Seychelles, (g) sanctioned countries under the OFAC and (h) any
other jurisdiction which prohibits the possession, dissemination or
communication of the Whitepaper.
This press release includes statements concerning Aptorum Group
Limited and its future expectations, plans and prospects that
constitute “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995. For this purpose,
any statements contained herein that are not statements of
historical fact may be deemed to be forward-looking statements. In
some cases, you can identify forward-looking statements by terms
such as “may,” “should,” “expects,” “plans,” “anticipates,”
“could,” “intends,” “target,” “projects,” “contemplates,”
“believes,” “estimates,” “predicts,” “potential,” or “continue,” or
the negative of these terms or other similar expressions. Aptorum
Group has based these forward-looking statements largely on its
current expectations and projections about future events and trends
that it believes may affect its business, financial condition and
results of operations. These forward-looking statements speak only
as of the date of this press release and are subject to a number of
risks, uncertainties and assumptions including, without limitation,
risks related to its announced management and organizational
changes, the continued service and availability of key personnel,
its ability to expand its product assortments by offering
additional products for additional consumer segments, the company’s
anticipated growth strategies, anticipated trends and challenges in
its business, and its expectations regarding, and the stability of,
its supply chain, and the risks more fully described in Aptorum
Group’s Form 20-F and other filings that Aptorum Group may make
with the SEC in the future. Aptorum Group assumes no obligation to
update any forward-looking statements contained in this press
release as a result of new information, future events or
otherwise.
This communication shall not constitute an offer to sell or the
solicitation of an offer to buy any securities, nor shall there be
any sale of securities in any jurisdiction in which the offer,
solicitation or sale would be unlawful prior to the registration or
qualification under the securities laws of any such
jurisdiction.
Investors must rely on their own evaluation of Aptorum and its
securities, including the merits and risks involved. Nothing
contained herein is or shall be relied on as, a promise or
representation as to the future performance of Aptorum Group or
Smart Pharma group.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190708005227/en/
For Aptorum Group Limited Investor Relations and Media
Tel: +852 2117 6611 Email: investor.relations@aptorumgroup.com
Website: http://www.aptorumgroup.com
For Smart Pharma Information Request Tel: +852 2117 6611
Email: info@smtph.com Website: http://www.smtph.com
Aptorum (NASDAQ:APM)
過去 株価チャート
から 3 2024 まで 4 2024
Aptorum (NASDAQ:APM)
過去 株価チャート
から 4 2023 まで 4 2024